|
시장보고서
상품코드
1424092
오피오이드 유발성 변비 시장, 점유율, 규모, 동향, 산업 분석 보고서 : 활성 성분별, 처방 유형별, 투여 경로별, 유통 채널별, 지역별, 부문별 예측(2024-2032년)Opioid Induced Constipation Market Share, Size, Trends, Industry Analysis Report, By Active Ingredients; By Prescription Type; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032 |
||||||
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
Polaris Market Research의 최신 조사에 따르면, 세계 오피오이드 유발성 변비 시장 규모는 2032년까지 39억 3,000만 달러에 달할 것으로 예상됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 통찰력과 미래 시장 성장에 대한 분석을 제공합니다.
오피오이드는 모르핀, 트르라마돌, 펜타닐을 함유하고 있어 통증 완화를 위해 가장 많이 사용됩니다. 소매점 및 온라인 전자상거래 플랫폼에서 진통제를 쉽게 구할 수 있게 된 것은 오피오이드 유발성 변비의 상당한 성장 잠재력을 포함하여 시장에서의 오피오이드 수요에 긍정적인 영향을 미치고 있습니다.
제약사, 정부 및 비정부기구의 인식 개선 캠페인이 증가하면서 오피오이드 유발성 변비 시장에 긍정적인 영향을 미치고 있습니다. 예를 들어, 2023년 제약회사 살릭스 파마슈티컬스(Salix Pharmaceuticals)는 다른 두 개의 비영리 단체와 함께 12월 5일을 오피오이드 유발성 변비 인식 개선의 날로 정하고 이 문제를 둘러싼 오명에 맞서겠다고 선언했습니다.
많은 소비자들 사이에서 오피오이드 사용이 증가함에 따라 오피오이드 유발성 변비 치료에 대한 수요가 증가할 것으로 예상됩니다. 현재 입수 가능한 데이터에 따르면, 암이 아니더라도 오피오이드 복용자 중 약 40-60%가 오피오이드 유발성 변비(OIC)를 앓고 있는 것으로 나타났습니다.
오피오이드 관련 약물 복용에 따른 변비 위험이 높고, 잠재적 원인과 적절한 치료법을 찾기 위한 연구가 증가함에 따라 시장 성장 기회가 확대되고 있습니다. 예를 들어, 국립의학도서관(National Library of Medicine)에 게재된 한 연구는 오피오이드 유발성 변비에 대해 조사했으며, 이 질환을 치료할 수 있는 잠재적 치료법과 비치료법을 검토했습니다.
또한, 오피오이드의 사용은 암 환자가 통증 완화를 위해 점점 더 많이 사용하는 것과 관련이 있을 수 있습니다. 제약 전문가들에 따르면 암 치료를 위해 오피오이드를 복용한 환자의 약 60-90%가 오피오이드로 인한 변비를 앓고 있다고 합니다. 오피오이드 유발성 변비 환자는 주로 암 통증에 직면 한 사람들에게 일상 생활 활동에 더 많은 어려움을 겪을 가능성이 높습니다.
또한, 연구 활동은 오피오이드 유발성 변비로 고통받는 환자들을 위한 효과적인 치료법을 개발하는 데 긍정적인 영향을 미치고 있습니다. 예를 들어, 2024년 연구는 오피오이드 유발성 변비와 쥐의 대장 신경총에서 P2Y1 수용체와의 관계를 규명하는 데 초점을 맞추었습니다.
오피오이드 유발성 변비 시장 보고서 하이라이트
아편유발성 변비 치료제로서의 가능성으로 인해 나록세골 부문이 가장 빠른 속도로 성장할 것으로 예상됩니다.
의사 진료의 중요성이 높아짐에 따라 처방약 부문이 가장 큰 비중을 차지할 것으로 예상됩니다.
경구제 부문은 주로 치료 섭취의 용이성과 높은 효과로 인해 시장을 독점하고 있습니다.
아시아태평양은 고령 인구 비율이 높아 가장 빠른 속도로 성장할 것으로 보입니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 오피오이드 유발성 변비 시장 인사이트
- 오피오이드 유발성 변비 - 업계 현황
- 오피오이드 유발성 변비 시장 역학
- 성장 촉진요인과 기회
- 성장 억제요인과 과제
- PESTLE 분석
- 오피오이드 유발성 변비 업계 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 세계의 오피오이드 유발성 변비 시장 : 유효 성분별
- 주요 조사 결과
- 서론
- Naloxegol
- Lubiprostone
- Methylnaltrexone Bromide
- Docusate Sodium
- 기타
제6장 세계의 오피오이드 유발성 변비 시장, 처방 유형별
- 주요 조사 결과
- 서론
- 시판약
- 처방전 및 자연 요법
제7장 세계의 오피오이드 유발성 변비 시장, 투여 경로별
- 주요 조사 결과
- 서론
- 경구
- 비경구
- 기타
제8장 세계의 오피오이드 유발성 변비 시장, 유통 채널별
- 주요 조사 결과
- 서론
- 병원 약국
- 온라인 약국
- 소매 약국
제9장 세계의 오피오이드 유발성 변비 시장, 지역별
- 주요 조사 결과
- 서론
- 오피오이드 유발성 변비 시장 평가, 지역,2019-2032년
- 오피오이드 유발성 변비 시장 - 북미
- 북미 : 오피오이드 유발성 변비 시장, 유효 성분별, 2019-2032년
- 북미 : 오피오이드 유발성 변비 시장, 유통 채널별, 2019-2032년
- 북미 : 오피오이드 유발성 변비 시장, 처방 유형별, 2019-2032년
- 북미 : 오피오이드 유발성 변비 시장, 투여 경로별, 2019-2032년
- 오피오이드 유발성 변비 시장 - 미국
- 오피오이드 유발성 변비 시장 - 캐나다
- 오피오이드 유발성 변비 시장 - 유럽
- 유럽 : 오피오이드 유발성 변비 시장, 유효 성분별, 2019-2032년
- 유럽 : 오피오이드 유발성 변비 시장, 유통 채널별, 2019-2032년
- 유럽 : 오피오이드 유발성 변비 시장, 처방 유형별, 2019-2032년
- 유럽 : 오피오이드 유발성 변비 시장, 투여 경로별, 2019-2032년
- 오피오이드 유발성 변비 시장 - 영국
- 오피오이드 유발성 변비 시장 - 프랑스
- 오피오이드 유발성 변비 시장 - 독일
- 오피오이드 유발성 변비 시장 - 이탈리아
- 오피오이드 유발성 변비 시장 - 스페인
- 오피오이드 유발성 변비 시장 - 네덜란드
- 오피오이드 유발성 변비 시장 - 러시아
- 오피오이드 유발성 변비 시장 - 아시아태평양
- 아시아태평양 : 오피오이드 유발성 변비 시장, 유효 성분별, 2019-2032년
- 아시아태평양 : 오피오이드 유발성 변비 시장, 유통 채널별, 2019-2032년
- 아시아태평양 : 오피오이드 유발성 변비 시장, 처방 유형별, 2019-2032년
- 아시아태평양 : 오피오이드 유발성 변비 시장, 투여 경로별, 2019-2032년
- 오피오이드 유발성 변비 시장 - 중국
- 오피오이드 유발성 변비 시장 - 인도
- 오피오이드 유발성 변비 시장 - 일본
- 오피오이드 유발성 변비 시장 - 말레이시아
- 오피오이드 유발성 변비 시장 - 인도네시아
- 오피오이드 유발성 변비 시장 - 한국
- 오피오이드 유발성 변비 시장 - 중동 및 아프리카
- 중동 및 아프리카 : 오피오이드 유발성 변비 시장, 유효 성분별, 2019-2032년
- 중동 및 아프리카 : 오피오이드 유발성 변비 시장, 유통 채널별, 2019-2032년
- 중동 및 아프리카 : 오피오이드 유발성 변비 시장, 처방 유형별, 2019-2032년
- 중동 및 아프리카 : 오피오이드 유발성 변비 시장, 투여 경로별, 2019-2032년
- 오피오이드 유발성 변비 시장 - 사우디아라비아
- 오피오이드 유발성 변비 시장 - 남아프리카
- 오피오이드 유발성 변비 시장 - 이스라엘
- 오피오이드 유발성 변비 시장 - 아랍에미리트(UAE)
- 오피오이드 유발성 변비 시장 - 라틴아메리카
- 라틴아메리카 : 오피오이드 유발성 변비 시장, 유효 성분별, 2019-2032년
- 라틴아메리카 : 오피오이드 유발성 변비 시장, 유통 채널별, 2019-2032년
- 라틴아메리카 : 오피오이드 유발성 변비 시장, 처방 유형별, 2019-2032년
- 라틴아메리카 : 오피오이드 유발성 변비 시장, 투여 경로별, 2019-2032년
- 오피오이드 유발성 변비 시장 - 멕시코
- 오피오이드 유발성 변비 시장 - 브라질
- 오피오이드 유발성 변비 시장 - 아르헨티나
제10장 경쟁 구도
- 확장 및 인수 분석
- 확장
- 인수
- 제휴/협업/합의/공개
제11장 기업 개요
- Abbott(US)
- Aurobindo Pharma(India)
- Bayer AG(Germany)
- Boehringer Ingelheim International GmbH.(Germany)
- Bristol Myers Squibb Company(US)
- Cosmo Pharmaceuticals(Ireland)
- Daewoong Pharmaceutical Company(South Korea)
- F. Hoffmann-La Roche Ltd(Switzerland)
- Fresenius Kabi AG(Germany)
- GSK Plc.(UK)
- Hikma Pharmaceuticals PLC(UK)
- Merck & Co Inc.(US)
- Mylan NV(US)
- Novartis AG(Switzerland)
- Pfizer Inc(US)
The global opioid induced constipation market size is expected to reach USD 3.93 billion by 2032, according to a new study by Polaris Market Research. The report "Opioid Induced Constipation Market Share, Size, Trends, Industry Analysis Report, By Active Ingredients; By Prescription Type; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Opioids are most used to get relief from pain, as they include morphine, tramadol, and fentanyl. The increased accessibility of painkillers at retail and online e-commerce platforms is showing a positive impact on the demand for opioids in the marketplace, including significant growth potential for opioid-induced constipation.
The rising awareness campaigns by pharmaceutical companies, governments, and non-government agencies are demonstrating a positive impact on the opioid-induced constipation market. For instance, in 2023, Salix Pharmaceuticals, a drug manufacturer, along with the other two non-profit organisations, declared December 5 as the opioid-induced constipation awareness day to confront the stigmas surrounding the issue.
The rising use of opioids among the larger consumer base is expected to boost demand for opioid-induced constipation treatment. According to the available data, among the individuals who consumed opioids without cancer, around 40-60% of the people get opioid-induced constipation (OIC).
The higher risk of constipation with the intake of opioid-related drugs, along with the growing research studies to review the potential causes and suitable treatments, are showing wider growth opportunities for the market. For instance, a study published in the National Library of Medicine explored opioid-induced constipation and reviewed potential therapeutic and non-therapeutic treatments to treat the disease.
Furthermore, the use of opioids can be related to the rising use by cancer patients to get pain relief. According to pharmaceutical experts, approximately 60 to 90% of patients who took the opioid for cancer treatment suffered from opioid-induced constipation. Opioid-induced constipation patients are likely to face more difficulties in day-to-day life activities, primarily those facing cancer pain.
Moreover, research activities are positively influencing the creation of effective treatments for patients suffering from opioid-induced constipation. For instance, a 2024 study focused on finding the relationship between opioid-induced constipation and the P2Y1 receptor in the colonic myenteric plexus of rats.
Opioid Induced Constipation Market Report Highlights
Naloxegol segment will grow at the fastest pace, due to its potential for treating opioid induced constipation issues.
Prescription segment held the largest share, owing to the rising importance of doctor consultation.
Oral segment dominated the market, primarily due to its ease of treatment intake and higher effectiveness.
Asia Pacific will register the fastest pace, attributable to the presence of the large proportion of elderly population.
The global players include Abbott, Aurobindo Pharma, Bayer, Boehringer Ingelheim International, & Bristol Myers Squibb Company.
Polaris Market Research has segmented the opioid induced constipation market report based on active ingredients, prescription type, route of administration, distribution channel and region:
Opioid Induced Constipation, Active Ingredients Outlook (Revenue - USD Billion, 2019 - 2032)
- Naloxegol
- Lubiprostone
- Methylnaltrexone Bromide
- Docusate Sodium
- Others
Opioid Induced Constipation, Prescription Type Outlook (Revenue - USD Billion, 2019 - 2032)
- Over The Counter Medicines
- Prescription, Natural Remedies
Opioid Induced Constipation, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)
- Oral
- Injectable
- Others
Opioid Induced Constipation, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Opioid Induced Constipation, Regional Outlook (Revenue - USD Billion, 2019 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Latin America
- Argentina
- Brazil
- Mexico
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Opioid Induced Constipation Market Insights
- 4.1. Opioid Induced Constipation - Industry Snapshot
- 4.2. Opioid Induced Constipation Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. The presence of an elderly population
- 4.2.1.2. The significant rise in opioid prescriptions
- 4.2.2. Restraints and Challenges
- 4.2.2.1. The declining use of opioids in the marketplace
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTLE Analysis
- 4.5. Opioid Induced Constipation Industry Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Opioid Induced Constipation Market, by Active Ingredients
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 5.3. Naloxegol
- 5.3.1. Global Opioid Induced Constipation Market, by Naloxegol, by Region, 2019-2032 (USD Billion)
- 5.4. Lubiprostone
- 5.4.1. Global Opioid Induced Constipation Market, by Lubiprostone, by Region, 2019-2032 (USD Billion)
- 5.5. Methylnaltrexone Bromide
- 5.5.1. Global Opioid Induced Constipation Market, by Methylnaltrexone Bromide, by Region, 2019-2032 (USD Billion)
- 5.6. Docusate Sodium
- 5.6.1. Global Opioid Induced Constipation Market, by Docusate Sodium, by Region, 2019-2032 (USD Billion)
- 5.7. Others
- 5.7.1. Global Opioid Induced Constipation Market, by Others, by Region, 2019-2032 (USD Billion)
6. Global Opioid Induced Constipation Market, by Prescription Type
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 6.3. Over The Counter Medicines
- 6.3.1. Global Opioid Induced Constipation Market, by Over The Counter Medicines, by Region, 2019-2032 (USD Billion)
- 6.4. Prescription, Natural Remedies
- 6.4.1. Global Opioid Induced Constipation Market, by Prescription, Natural Remedies, by Region, 2019-2032 (USD Billion)
7. Global Opioid Induced Constipation Market, by Route of Administration
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.3. Oral
- 7.3.1. Global Opioid Induced Constipation Market, by Oral, by Region, 2019-2032 (USD Billion)
- 7.4. Parenteral
- 7.4.1. Global Opioid Induced Constipation Market, by Parenteral, by Region, 2019-2032 (USD Billion)
- 7.5. Others
- 7.5.1. Global Opioid Induced Constipation Market, by Others, by Region, 2019-2032 (USD Billion)
8. Global Opioid Induced Constipation Market, by Distribution Channel
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Global Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.3. Hospital Pharmacy
- 8.3.1. Global Opioid Induced Constipation Market, by Hospital Pharmacy, by Region, 2019-2032 (USD Billion)
- 8.4. Online Pharmacy
- 8.4.1. Global Opioid Induced Constipation Market, by Online Pharmacy, by Region, 2019-2032 (USD Billion)
- 8.5. Retail Pharmacy
- 8.5.1. Global Opioid Induced Constipation Market, by Retail Pharmacy, by Region, 2019-2032 (USD Billion)
9. Global Opioid Induced Constipation Market, by Geography
- 9.1. Key findings
- 9.2. Introduction
- 9.2.1. Opioid Induced Constipation Market Assessment, By Geography, 2019-2032 (USD Billion)
- 9.3. Opioid Induced Constipation Market - North America
- 9.3.1. North America: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.3.2. North America: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.3.3. North America: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.3.4. North America: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 9.3.5. Opioid Induced Constipation Market - U.S.
- 9.3.5.1. U.S.: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.3.5.2. U.S.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.3.5.3. U.S.: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.3.5.4. U.S.: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 9.3.6. Opioid Induced Constipation Market - Canada
- 9.3.6.1. Canada: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.3.6.2. Canada: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.3.6.3. Canada: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.3.6.4. Canada: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 9.4. Opioid Induced Constipation Market - Europe
- 9.4.1. Europe: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.4.2. Europe: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.4.3. Europe: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.4.4. Europe: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 9.4.5. Opioid Induced Constipation Market - UK
- 9.4.5.1. UK: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.4.5.2. UK: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.4.5.3. UK: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.4.5.4. UK: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 9.4.6. Opioid Induced Constipation Market - France
- 9.4.6.1. France: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.4.6.2. France: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.4.6.3. France: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.4.6.4. France: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 9.4.7. Opioid Induced Constipation Market - Germany
- 9.4.7.1. Germany: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.4.7.2. Germany: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.4.7.3. Germany: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.4.7.4. Germany: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 9.4.8. Opioid Induced Constipation Market - Italy
- 9.4.8.1. Italy: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.4.8.2. Italy: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.4.8.3. Italy: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.4.8.4. Italy: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 9.4.9. Opioid Induced Constipation Market - Spain
- 9.4.9.1. Spain: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.4.9.2. Spain: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.4.9.3. Spain: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.4.9.4. Spain: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 9.4.10. Opioid Induced Constipation Market - Netherlands
- 9.4.10.1. Netherlands: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.4.10.2. Netherlands: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.4.10.3. Netherlands: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.4.10.4. Netherlands: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 9.4.11. Opioid Induced Constipation Market - Russia
- 9.4.11.1. Russia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.4.11.2. Russia.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.4.11.3. Russia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.4.11.4. Russia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 9.5. Opioid Induced Constipation Market - Asia Pacific
- 9.5.1. Asia Pacific: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.5.2. Asia Pacific: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.5.3. Asia Pacific: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.5.4. Asia Pacific: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 9.5.5. Opioid Induced Constipation Market - China
- 9.5.5.1. China: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.5.5.2. China.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.5.5.3. China: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.5.5.4. China: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 9.5.6. Opioid Induced Constipation Market - India
- 9.5.6.1. India: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.5.6.2. India.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.5.6.3. India: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.5.6.4. India: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 9.5.7. Opioid Induced Constipation Market - Japan
- 9.5.7.1. Japan: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.5.7.2. Japan.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.5.7.3. Japan: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.5.7.4. Japan: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 9.5.8. Opioid Induced Constipation Market - Malaysia
- 9.5.8.1. Malaysia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.5.8.2. Malaysia.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.5.8.3. Malaysia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.5.8.4. Malaysia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 9.5.9. Opioid Induced Constipation Market - Indonesia
- 9.5.9.1. Indonesia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.5.9.2. Indonesia.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.5.9.3. Indonesia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.5.9.4. Indonesia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 9.5.10. Opioid Induced Constipation Market - South Korea
- 9.5.10.1. South Korea: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.5.10.2. South Korea.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.5.10.3. South Korea: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.5.10.4. South Korea: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 9.6. Opioid Induced Constipation Market - Middle East & Africa
- 9.6.1. Middle East & Africa: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.6.2. Middle East & Africa: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.6.3. Middle East & Africa: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.6.4. Middle East & Africa: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 9.6.5. Opioid Induced Constipation Market - Saudi Arabia
- 9.6.5.1. Saudi Arabia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.6.5.2. Saudi Arabia: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.6.5.3. Saudi Arabia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.6.5.4. Saudi Arabia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 9.6.6. Opioid Induced Constipation Market - South Africa
- 9.6.6.1. South Africa: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.6.6.2. South Africa: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.6.6.3. South Africa: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.6.6.4. South Africa: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 9.6.7. Opioid Induced Constipation Market - Israel
- 9.6.7.1. Israel: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.6.7.2. Israel: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.6.7.3. Israel: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.6.7.4. Israel: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 9.6.8. Opioid Induced Constipation Market - UAE
- 9.6.8.1. UAE: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.6.8.2. UAE: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.6.8.3. UAE: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.6.8.4. UAE: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 9.7. Opioid Induced Constipation Market - Latin America
- 9.7.1. Latin America: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.7.2. Latin America: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.7.3. Latin America: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.7.4. Latin America: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 9.7.5. Opioid Induced Constipation Market - Mexico
- 9.7.5.1. Mexico: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.7.5.2. Mexico: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.7.5.3. Mexico: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.7.5.4. Mexico: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 9.7.6. Opioid Induced Constipation Market - Brazil
- 9.7.6.1. Brazil: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.7.6.2. Brazil: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.7.6.3. Brazil: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.7.6.4. Brazil: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
- 9.7.7. Opioid Induced Constipation Market - Argentina
- 9.7.7.1. Argentina: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
- 9.7.7.2. Argentina: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.7.7.3. Argentina: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
- 9.7.7.4. Argentina: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
10. Competitive Landscape
- 10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
- 10.2. Partnerships/Collaborations/Agreements/Exhibitions
11. Company Profiles
- 11.1. Abbott (US)
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
- 11.2. Aurobindo Pharma (India)
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
- 11.3. Bayer AG (Germany)
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
- 11.4. Boehringer Ingelheim International GmbH. (Germany)
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
- 11.5. Bristol Myers Squibb Company (US)
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
- 11.6. Cosmo Pharmaceuticals (Ireland)
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
- 11.7. Daewoong Pharmaceutical Company (South Korea)
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
- 11.8. F. Hoffmann-La Roche Ltd (Switzerland)
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
- 11.9. Fresenius Kabi AG (Germany)
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
- 11.10. GSK Plc. (UK)
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development
- 11.11. Hikma Pharmaceuticals PLC (UK)
- 11.11.1. Company Overview
- 11.11.2. Financial Performance
- 11.11.3. Product Benchmarking
- 11.11.4. Recent Development
- 11.12. Merck & Co Inc. (US)
- 11.12.1. Company Overview
- 11.12.2. Financial Performance
- 11.12.3. Product Benchmarking
- 11.12.4. Recent Development
- 11.13. Mylan NV (US)
- 11.13.1. Company Overview
- 11.13.2. Financial Performance
- 11.13.3. Product Benchmarking
- 11.13.4. Recent Development
- 11.14. Novartis AG (Switzerland)
- 11.14.1. Company Overview
- 11.14.2. Financial Performance
- 11.14.3. Product Benchmarking
- 11.14.4. Recent Development
- 11.15. Pfizer Inc (US)
- 11.15.1. Company Overview
- 11.15.2. Financial Performance
- 11.15.3. Product Benchmarking
- 11.15.4. Recent Development
샘플 요청 목록